Study highlights need for early detection and timely treatment of ATTR-CM
Early recognition of ATTR-CM and the timely initiation of treatment can help secure better patient outcomes.
News
-
-
Pairing GLP-1 receptor agonists with SGLT2 inhibitors lowers risk of death in ATTR-CM
Patients with ATTR-CM who took both GLP-1RA and SGLT2i had lower death rates and fewer heart events than those on SGLT2i alone.
-
AI tools could lead to earlier ATTR-CM diagnosis, with no racial bias
AI tools could help doctors to detect transthyretin amyloid cardiomyopathy (ATTR-CM) earlier and more fairly across different racial groups.
-
ATTR-CM may contribute to death in patients with Alzheimer’s disease
Cardiac transthyretin amyloidosis (ATTR-CM) was found in 12% of patients with Alzheimer’s disease and heart enlargement after death.
-
Tafamidis shows promise for mixed-phenotype ATTR-CM
Tafamidis helps people with mixed-phenotype ATTR-CM live longer with fewer heart-related hospitalizations and deaths.
-
Upcoming clinical trial will assess nucresiran in ATTR-CM
A new clinical trial evaluating the efficacy of nucresiran in treating transthyretin amyloid cardiomyopathy (ATTR-CM) is set to launch soon.
-
Patisiran improves the functional capacity of individuals with ATTR-CM, study finds
Patisiran led to improved functional status and quality of life among patients with ATTR-CM.
-
Nerve symptoms in ATTR-CM may signal higher risk of heart complications
For patients with ATTR-CM, nerve symptoms — known as autonomic dysfunction — could be a warning sign of more serious heart trouble ahead.
-
AI has potential to revolutionize how cardiac amyloidosis is diagnosed, researchers say
AI may be a game changer when it comes to recognizing and diagnosing cardiac amyloidosis, according to a new study.
-
SGLTis associated with decreased mortality in ATTR-CM
The use of SGLTis, a drug class commonly prescribed for diabetes and heart failure, appears to decrease mortality in ATTR-CM.
